Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments

Weili Wang, Huizhen Zheng, Jun Jiang, Zhi Li, Dongpeng Jiang, Xiangru Shi, Hui Wang, Jie Jiang, Qianqian Xie, Meng Gao, Jianhong Chu, Xiaoming Cai, Tian Xia, Ruibin LiNature Communications 2022 · DOI

Abstract

While hypoxia promotes carcinogenesis, tumour aggressiveness, metastasis, and resistance to oncological treatments, the impacts of hyperoxia on tumours are rarely explored because providing a long-lasting oxygen supply in vivo is a major challenge. Herein, we construct micro oxygen factories, namely, photosynthesis microcapsules (PMCs), by encapsulation of acquired cyanobacteria and upconversion nanoparticles in alginate microcapsules. This system enables a long-lasting oxygen supply through the conversion of external radiation into red-wavelength emissions for photosynthesis in cyanobacteria. PMC treatment suppresses the NF-kB pathway, HIF-1α production and cancer cell proliferation. Hyperoxic microenvironment created by an in vivo PMC implant inhibits hepatocarcinoma growth and metastasis and has synergistic effects together with anti-PD-1 in breast cancer. The engineering oxygen factories offer potential for tumour biology studies in hyperoxic microenvironments and inspire the exploration of oncological treatments.

Introduction

Most solid tumors are characterized by hypoxia, a low-oxygen state that serves as a survival strategy for cancer cells. Hypoxia triggers the production of proteins like HIF-1α, which promote angiogenesis, metabolic shifts, and immune evasion, rendering tumors more aggressive and resistant to standard therapies. While reversing this state through hyperoxia could theoretically inhibit tumor progression, maintaining a steady, biocompatible oxygen supply deep within a tumor remains a significant engineering hurdle. Traditional methods, such as hyperbaric oxygen chambers, often lack the necessary specificity and efficiency for long-term treatment.

Methods: Constructing the Photosynthesis Microcapsule (PMC)

To address the challenge of in-situ oxygenation, researchers developed Photosynthesis Microcapsules (PMCs). This multi-component system functions as an internal oxygen factory:

  1. Biological Engine: A strain of cyanobacteria (Synechocystis sp. 6803) was "evolved" through stepwise acclimation to survive at 37°C in mammalian physiological conditions.
  2. Light Conversion: Because red light (required for photosynthesis) has poor tissue penetration, Upconversion Nanoparticles (UCNPs) were integrated. These particles absorb deep-penetrating near-infrared (NIR) light (980 nm) and convert it into the red-wavelength emissions needed by the bacteria.
  3. Encapsulation: These components were housed in alginate-calcium microcapsules coated with poly-L-lysine (PLL). This structure prevents microbial leakage while allowing oxygen to diffuse freely into the surrounding tumor tissue.
Schematic illustration of the construction of Photosynthesis Microcapsules (PMCs) involving cyanobacteria, UCNPs, and alginate encapsulation.

Key Results and In Vivo Performance

The PMCs were validated across multiple biological models, including nine cancer cell lines and in vivo rabbit and mouse models. The system demonstrated a highly tunable oxygen production rate controlled by external NIR laser intensity.

  • Superior Oxygenation: In tumor cores, NIR-PMC treatment achieved oxygen levels 6.7-fold higher than those achieved by hyperbaric oxygen therapy. Unlike transient methods, PMCs provided a sustained hyperoxic environment over several days.
  • Tumor and Metastasis Inhibition: In a rabbit hepatocarcinoma model, the combination of PMCs and NIR light almost completely inhibited tumor growth over 14 days and dramatically reduced lung metastases. Notably, 20% of the treated rabbits survived beyond 140 days, compared to 0% in the control group.
  • Immunotherapy Synergy: In an orthotopic breast cancer model, PMCs significantly enhanced the efficacy of anti-PD-1 immunotherapy, leading to an 80% survival rate at 60 days. This synergy is attributed to the normalization of oxygen levels, which reinvigorates T-cells and Natural Killer (NK) cells.
In vivo oxygenation performance of PMCs, showing sustained pO2 levels and tumor re-oxygenation compared to controls.

Mechanistic Insights

The hyperoxic microenvironment created by PMCs actively disrupts the tumor's survival mechanisms. It suppresses the NF-κB and HIF-1α pathways, which are master regulators of cancer cell proliferation under stress. Furthermore, hyperoxia reduces levels of adenosine, a molecule tumors use to suppress the immune system. By lowering adenosine, PMCs effectively strip away the tumor's chemical shield, allowing the immune system to recognize and attack the cancer more effectively.

Limitations and Future Directions

While 980 nm NIR light offers better penetration than visible light, its reach remains limited for very deep-seated human tumors. Future research may explore NIR-II (1200–1700 nm) light sources for deeper tissue access. Additionally, while direct intratumoral injection was used here, clinical translation may require more sophisticated delivery methods, such as transcatheter arterial chemoembolization (TACE). Long-term biosafety studies regarding the fate of the cyanobacteria and nanoparticles are also necessary before human trials can proceed.

Summary updated

Abstract

While hypoxia promotes carcinogenesis, tumour aggressiveness, metastasis, and resistance to oncological treatments, the impacts of hyperoxia on tumours are rarely explored because providing a long-lasting oxygen supply in vivo is a major challenge. Herein, we construct micro oxygen factories, namely, photosynthesis microcapsules (PMCs), by encapsulation of acquired cyanobacteria and upconversion nanoparticles in alginate microcapsules. This system enables a long-lasting oxygen supply through the conversion of external radiation into red-wavelength emissions for photosynthesis in cyanobacteria. PMC treatment suppresses the NF-kB pathway, HIF-1α production and cancer cell proliferation. Hyperoxic microenvironment created by an in vivo PMC implant inhibits hepatocarcinoma growth and metastasis and has synergistic effects together with anti-PD-1 in breast cancer. The engineering oxygen factories offer potential for tumour biology studies in hyperoxic microenvironments and inspire the exploration of oncological treatments.
BibTeX
@inproceedings{wang2022engineering,
  author = {Weili Wang and Huizhen Zheng and Jun Jiang and Zhi Li and Dongpeng Jiang and Xiangru Shi and Hui Wang and Jie Jiang and Qianqian Xie and Meng Gao and Jianhong Chu and Xiaoming Cai and Tian Xia and Ruibin Li},
  title = {{Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-32066-w},
}
Figure